Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Beginning Cash Balance: 2010-2025

Historic Beginning Cash Balance for Anika Therapeutics (ANIK) over the last 16 years, with Sep 2025 value amounting to $53.2 million.

  • Anika Therapeutics' Beginning Cash Balance fell 15.37% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.4 million, marking a year-over-year decrease of 11.72%. This contributed to the annual value of $71.3 million for FY2024, which is 13.22% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Beginning Cash Balance is $53.2 million, which was down 0.38% from $53.4 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Beginning Cash Balance ranged from a high of $97.2 million in Q3 2021 and a low of $53.2 million during Q3 2025.
  • For the 3-year period, Anika Therapeutics' Beginning Cash Balance averaged around $66.0 million, with its median value being $65.1 million (2023).
  • Examining YoY changes over the last 5 years, Anika Therapeutics' Beginning Cash Balance showed a top increase of 43.70% in 2021 and a maximum decrease of 39.15% in 2021.
  • Over the past 5 years, Anika Therapeutics' Beginning Cash Balance (Quarterly) stood at $91.0 million in 2021, then declined by 3.52% to $87.8 million in 2022, then dropped by 24.21% to $66.5 million in 2023, then fell by 8.55% to $60.8 million in 2024, then decreased by 15.37% to $53.2 million in 2025.
  • Its Beginning Cash Balance stands at $53.2 million for Q3 2025, versus $53.4 million for Q2 2025 and $57.2 million for Q1 2025.